VAXCYTE INC
PCVXNASDAQTrading Snapshot
- Day Range
- $58.45 – $59.80
- 52-Week Range
- $29.29 – $65.00
- Volume
- $2.71B
- Avg Volume
- $3.22B
- Shares Outstanding
- 144.4M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $814M
- Last Q Revenue
- $212M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-7.64
- Dividend Yield
- —
Why Investors Own PCVX
- ✓High-growth profile — revenue up +52.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About VAXCYTE INC
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential
Vaxcyte's VAX-31 is in a Phase 3 pivotal OPUS-1 noninferiority trial and is expecting topline data in 4Q 2026. Learn more about PCVX stock here.